Polysaccharide-coated liposomal amphotericin B for the treatment of murine pulmonary candidiasis

Tohoku J Exp Med. 1992 Nov;168(3):483-90. doi: 10.1620/tjem.168.483.

Abstract

Amylopectin-coated liposomal amphotericin B was investigated in a murine model of pulmonary candidiasis. The LD50 of amylopectin-coated liposomal amphotericin B in normal mice was more than 10.0 mg/kg, and that of conventional amphotericin B was 1.2 mg/kg. Amylopectin-coated liposomes showed twice the concentration in the lungs of conventional liposomes. Candida albicans was inoculated intratracheally into BALB/C mice. Twenty-four hours later, the number of Candida in the lungs of mice treated with amylopectin-coated liposomes was less than in those treated with conventional liposomes, and amylopectin-coated liposomes improved the survival rate of inoculated mice. Coating liposomes with amylopectin aids the targeting of amphotericin B to the lungs.

MeSH terms

  • Amphotericin B / pharmacokinetics
  • Amphotericin B / therapeutic use*
  • Amphotericin B / toxicity
  • Amylopectin / pharmacokinetics
  • Amylopectin / therapeutic use*
  • Amylopectin / toxicity
  • Animals
  • Candida albicans / growth & development
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Colony Count, Microbial
  • Liposomes
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / microbiology
  • Male
  • Mice
  • Mice, Inbred BALB C

Substances

  • Liposomes
  • Amphotericin B
  • Amylopectin